stockrow
Saturday 7 November 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
- EPS
- +88.0%
- Free cash flow
- −16.6%
- Total debt
- −47.0%
Quarter to June 2026, against a year earlier
0.14
0.00
0.00%
Follow SLXN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | 0 | (1) | 1 | (5) | (17) | (12) | (14) | +127.4% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | 0 | (1) | 1 | (5) | (17) | (12) | (14) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (212.35) | (308.65) | 234.91 | (6,854.42) | (3,952.02) | (89.60) | (56.46) | (15.9%) | ||||||
| Cash flow | — | — | — | — | (83.33) | (586.33) | 326.56 | (6,470.00) | (1,999.05) | (81.35) | (18.09) | (0.5%) | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 94.29 | (5.24) | (0.07) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (83.33) | (586.33) | 326.56 | (6,375.71) | (2,004.29) | (81.41) | (18.09) | (0.5%) | ||||||
| Book value | — | — | — | — | (188.89) | (39.46) | (481.12) | 4,287.14 | (949.76) | 19.57 | 0.06 | n/m | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +171.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | 1 | (5) | (8) | (11) | (12) | +170.3% | |||||
| Capex | — | — | — | — | 0 | — | — | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | 0 | (1) | 1 | (4) | (8) | (11) | (12) | +170.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 0 | (1) | 3 | (1) | 4 | 0 | n/m | |||||
| Net debt | — | — | — | — | 0 | 0 | 0 | (5) | 2 | (4) | (2) | +143.8% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | 0 | (1) | 3 | (4) | 3 | 0 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (189.18) | (1.31) | 0.50 | (8.10) | (405.05) | (236.40) | (277.96) | (47.2) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (0.34) | 570.61 | (90.02) | 74.55 | 204.96 | 1,718.90 | (17,021.95) | +1,719.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 0 | 0 | 0 | 14 | 14 | — | +36.1% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Silexion Therapeutics Corp vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VIVS VivoSim Labs, Inc. | $2.3M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| HCWB HCW Biologics Inc. | $2.3M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| APVO Aptevo Therapeutics Inc. | $2.3M | — (loss-making) | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLXN Silexion Therapeutics Corp | $2.2M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | |
| BRTX Biorestorative Therapies, Inc. | $2.1M | — (loss-making) | — (loss-making) | −7.20% (below 0%: shrinking) | n/m | −35.26% (below 0%: shrinking) | 68.10% | (14,593.53%) | Compare |
| SILO Silo Pharma, Inc. | $2.1M | — (loss-making) | 18.4× | 0.00% | n/m | +39.17% (above 0%: growing) | (15.00%) | 0.00% | Compare |
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.0M | — (loss-making) | — (loss-making) | — | n/m | −62.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $2.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.2M | — | — | −3.60% | — | −9.86% | 0.00% | 0.00% |